MedTrace Logo

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

NCT02742532 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether oxytocin will decrease craving to use drugs/alcohol and stress reactivity following exposure to laboratory-induced stress among Active Duty Service Members with a dual diagnosis of alcohol/substance use disorder (ASUD) and post-traumatic anxiety.

Conditions

Interventions

DRUG

Oxytocin

Intranasal oxytocin 40 IU

DRUG

Placebo

Intranasal saline solution

Sponsors & Collaborators

  • United States Naval Medical Center, San Diego

    collaborator FED

  • United States Department of Defense

    collaborator FED

  • Congressionally Directed Medical Research Programs

    collaborator FED

  • Eisenhower Army Medical Center

    collaborator FED

  • Jennifer Mitchell

    lead OTHER

Principal Investigators

  • Mardi Smith, PhD · United States Naval Medical Center, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-20
Primary Completion
2019-07-01
Completion
2019-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742532 on ClinicalTrials.gov